NCT02423265View on ClinicalTrials.gov

Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2017

Conditions
Myocardial IschemiaCoronary Artery DiseaseArteriosclerosisChronic Stable Angina
Interventions
DRUG

Ranolazine

Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day

DRUG

Placebo

Matching placebo: up-titration after 1 week

Trial Locations (1)

27834

East Carolina Heart Institute at Vidant Medical Center, Greenville

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

East Carolina University

OTHER

NCT02423265 - Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries | Biotech Hunter | Biotech Hunter